Literature DB >> 20663404

Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis.

A E Thompson1, P G Bashook.   

Abstract

OBJECTIVES: Accurate communication of information concerning the risks and benefits of medications is essential for adherence and patient safety. A diverse array of information and sources makes it difficult to know exactly what to tell a patient with rheumatoid arthritis about methotrexate.
OBJECTIVE: Our objective is to determine what key information patients must know about methotrexate and the key reasons they should call their doctor while they are taking methotrexate.
METHODS: Three hundred and forty-four Canadian rheumatologists were sent a survey containing open-ended questions to gain uncued narrative perspectives from each individual's experience. The survey was designed to determine what must all patients taking methotrexate know and when must patients taking methotrexate call a physician? Emergent coding was used to establish a set of categories to form a checklist for coding. A second member checking survey was sent to gain confirmation and validation of themes developed from the initial survey.
RESULTS: One hundred and seventy out of 344 (49.5%) surveys were completed. Regular blood testing, once weekly dosing, risk of infection, pregnancy and lactation information, alcohol limitation, potential lung toxicity, and drug interactions were thought to be important. Patients should call if they became pregnant, developed symptoms suggestive of lung toxicity, developed an infection, severe mouth sores, or were concerned about any side effects warranting the discontinuation of the medication.
CONCLUSIONS: This study is the first to describe, from a rheumatologist's perspective, the key important information that all patients should know and when patients should call their doctor when taking methotrexate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663404

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  A Unique Interaction of Methotrexate and Nitrofurantoin Resulting in Irreversible Pulmonary Fibrosis.

Authors:  Smriti Kochhar; Veera Jayasree Latha Bommu; Mariusz Kocur; Viraj Shah; Pramil Cheriyath; Thomas Lake
Journal:  Cureus       Date:  2022-01-03

2.  Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.

Authors:  Marinella Patanè; Miriam Ciriaco; Serafina Chimirri; Francesco Ursini; Saverio Naty; Rosa Daniela Grembiale; Luca Gallelli; Giovambattista De Sarro; Emilio Russo
Journal:  Adv Pharmacol Sci       Date:  2013-05-12

3.  What factors could influence physicians' management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia.

Authors:  Catherine Nelson-Piercy; Ivo Vlaev; Katie Harris; Rebecca Fischer-Betz
Journal:  BMC Health Serv Res       Date:  2019-11-21       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.